Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA) CFO Tran Nguyen bought 2,200 shares of Prothena Co. PLC stock in a transaction dated Friday, May 9th. The shares were purchased at an average cost of $19.61 per share, with a total value of $43,142.00. Following the completion of the transaction, the chief financial officer now directly owns 2,200 shares in the company, valued at approximately $43,142. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on PRTA. Analysts at Wedbush upgraded shares of Prothena Co. PLC to a “best ideas list” rating in a research note on Friday, April 25th. Separately, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Prothena Co. PLC in a research note on Thursday, April 24th. They now have a $60.00 price target on the stock. Finally, analysts at Citigroup Inc. initiated coverage on shares of Prothena Co. PLC in a research note on Wednesday, April 9th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $43.75.

Shares of Prothena Co. PLC (NASDAQ:PRTA) traded up 7.64% on Monday, hitting $20.86. The stock had a trading volume of 295,156 shares. Prothena Co. PLC has a 52 week low of $8.20 and a 52 week high of $49.24. The stock has a 50-day moving average of $30.41 and a 200-day moving average of $29.57. The company’s market cap is $456.9 million. Prothena Co. PLC also was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 763,327 shares, a growth of 41.4% from the April 15th total of 539,731 shares. Approximately 3.5% of the shares of the company are short sold. Based on an average daily trading volume, of 835,091 shares, the short-interest ratio is presently 0.9 days.

Prothena Co. PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.81 by $0.03.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.